Correspondence 0001628280-24-041574 from Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: Sept. 30, 2024 · CIK: 0001636282 · Accession: 0001628280-24-041574
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282252
Letter
Document
September 30, 2024
VIA EDGAR AND EMAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Doris Stacey Gama
Re: Spyre Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 20, 2024
File No. 333-282252
To Whom it May Concern:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company be accelerated to 4:15 p.m., Eastern Time, on October 2, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631.
Very truly yours,
SPYRE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document September 30, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Doris Stacey Gama Re: Spyre Therapeutics, Inc. Registration Statement on Form S-3 Filed September 20, 2024 File No. 333-282252 To Whom it May Concern: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company be accelerated to 4:15 p.m., Eastern Time, on October 2, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631. Very truly yours, SPYRE THERAPEUTICS, INC. By: /s/ Cameron Turtle Name: Cameron Turtle Title: Chief Executive Officer cc: Scott Burrows, Spyre Therapeutics, Inc. Heidy King-Jones, Spyre Therapeutics, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP